ROS1-rearranged lung cancer: A clinicopathologic and molecular study of 15 surgical cases

Akihiko Yoshida, Takashi Kohno, Koji Tsuta, Susumu Wakai, Yasuhito Arai, Yoko Shimada, Hisao Asamura, Koh Furuta, Tatsuhiro Shibata, Hitoshi Tsuda

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Recent discovery of ROS1 gene fusion in a subset of lung cancers has raised clinical interest, because ROS1 fusion-positive cancers are reportedly sensitive to kinase inhibitors. To better understand these tumors, we examined 799 surgically resected non-small cell lung cancers by reverse transcriptase polymerase chain reaction and identified 15 tumors harboring ROS1 fusion transcripts (2.5% of adenocarcinomas). The most frequent fusion partner was CD74 followed by EZR. The affected patients were often younger nonsmoking female individuals, and they had overall survival rates similar to those of the ROS1 fusion-negative cancer patients. All the ROS1 fusion-positive tumors were adenocarcinomas except 1, which was an adenosquamous carcinoma. Histologic examination identified an at least focal presence of either solid growth with signet-ring cells or cribriform architecture with abundant extracellular mucus in 53% of the cases. These 2 patterns are reportedly also characteristic of anaplastic lymphoma kinase (ALK)-rearranged lung cancers, and our data suggest a phenotypic resemblance between the ROS1-rearranged and ALK-rearranged tumors. All tumors except 1 were immunoreactive to thyroid transcription factor-1. Fluorescence in situ hybridization using ROS1 break-apart probes revealed positive rearrangement signals in 23% to 93% of the tumor cells in ROS1 fusion-positive cancers, which were readily distinguished using a 15% cutoff value from 50 ROS1 fusion-negative tumors tested, which showed 0% to 6% rearrangement signals. However, this perfect test performance was achieved only when isolated 3′ signals were included along with classic split signals in the definition of rearrangement positivity. Fluorescence in situ hybridization signal patterns were unrelated to 5′ fusion partner genes. All ROS1 fusion-positive tumors lacked alteration of EGFR, KRAS, HER2, ALK, and RET genes.

Original languageEnglish
Pages (from-to)554-562
Number of pages9
JournalAmerican Journal of Surgical Pathology
Volume37
Issue number4
DOIs
Publication statusPublished - 2013 Apr
Externally publishedYes

Fingerprint

Lung Neoplasms
Neoplasms
Gene Fusion
Fluorescence In Situ Hybridization
Adenocarcinoma
Adenosquamous Carcinoma
Mucus
Reverse Transcriptase Polymerase Chain Reaction
Non-Small Cell Lung Carcinoma
Phosphotransferases
Survival Rate
Growth

Keywords

  • carcinoma
  • diagnosis
  • lung
  • ROS1

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

ROS1-rearranged lung cancer : A clinicopathologic and molecular study of 15 surgical cases. / Yoshida, Akihiko; Kohno, Takashi; Tsuta, Koji; Wakai, Susumu; Arai, Yasuhito; Shimada, Yoko; Asamura, Hisao; Furuta, Koh; Shibata, Tatsuhiro; Tsuda, Hitoshi.

In: American Journal of Surgical Pathology, Vol. 37, No. 4, 04.2013, p. 554-562.

Research output: Contribution to journalArticle

Yoshida, A, Kohno, T, Tsuta, K, Wakai, S, Arai, Y, Shimada, Y, Asamura, H, Furuta, K, Shibata, T & Tsuda, H 2013, 'ROS1-rearranged lung cancer: A clinicopathologic and molecular study of 15 surgical cases', American Journal of Surgical Pathology, vol. 37, no. 4, pp. 554-562. https://doi.org/10.1097/PAS.0b013e3182758fe6
Yoshida, Akihiko ; Kohno, Takashi ; Tsuta, Koji ; Wakai, Susumu ; Arai, Yasuhito ; Shimada, Yoko ; Asamura, Hisao ; Furuta, Koh ; Shibata, Tatsuhiro ; Tsuda, Hitoshi. / ROS1-rearranged lung cancer : A clinicopathologic and molecular study of 15 surgical cases. In: American Journal of Surgical Pathology. 2013 ; Vol. 37, No. 4. pp. 554-562.
@article{8efd2aefe0b14d3da0b839992278ceff,
title = "ROS1-rearranged lung cancer: A clinicopathologic and molecular study of 15 surgical cases",
abstract = "Recent discovery of ROS1 gene fusion in a subset of lung cancers has raised clinical interest, because ROS1 fusion-positive cancers are reportedly sensitive to kinase inhibitors. To better understand these tumors, we examined 799 surgically resected non-small cell lung cancers by reverse transcriptase polymerase chain reaction and identified 15 tumors harboring ROS1 fusion transcripts (2.5{\%} of adenocarcinomas). The most frequent fusion partner was CD74 followed by EZR. The affected patients were often younger nonsmoking female individuals, and they had overall survival rates similar to those of the ROS1 fusion-negative cancer patients. All the ROS1 fusion-positive tumors were adenocarcinomas except 1, which was an adenosquamous carcinoma. Histologic examination identified an at least focal presence of either solid growth with signet-ring cells or cribriform architecture with abundant extracellular mucus in 53{\%} of the cases. These 2 patterns are reportedly also characteristic of anaplastic lymphoma kinase (ALK)-rearranged lung cancers, and our data suggest a phenotypic resemblance between the ROS1-rearranged and ALK-rearranged tumors. All tumors except 1 were immunoreactive to thyroid transcription factor-1. Fluorescence in situ hybridization using ROS1 break-apart probes revealed positive rearrangement signals in 23{\%} to 93{\%} of the tumor cells in ROS1 fusion-positive cancers, which were readily distinguished using a 15{\%} cutoff value from 50 ROS1 fusion-negative tumors tested, which showed 0{\%} to 6{\%} rearrangement signals. However, this perfect test performance was achieved only when isolated 3′ signals were included along with classic split signals in the definition of rearrangement positivity. Fluorescence in situ hybridization signal patterns were unrelated to 5′ fusion partner genes. All ROS1 fusion-positive tumors lacked alteration of EGFR, KRAS, HER2, ALK, and RET genes.",
keywords = "carcinoma, diagnosis, lung, ROS1",
author = "Akihiko Yoshida and Takashi Kohno and Koji Tsuta and Susumu Wakai and Yasuhito Arai and Yoko Shimada and Hisao Asamura and Koh Furuta and Tatsuhiro Shibata and Hitoshi Tsuda",
year = "2013",
month = "4",
doi = "10.1097/PAS.0b013e3182758fe6",
language = "English",
volume = "37",
pages = "554--562",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - ROS1-rearranged lung cancer

T2 - A clinicopathologic and molecular study of 15 surgical cases

AU - Yoshida, Akihiko

AU - Kohno, Takashi

AU - Tsuta, Koji

AU - Wakai, Susumu

AU - Arai, Yasuhito

AU - Shimada, Yoko

AU - Asamura, Hisao

AU - Furuta, Koh

AU - Shibata, Tatsuhiro

AU - Tsuda, Hitoshi

PY - 2013/4

Y1 - 2013/4

N2 - Recent discovery of ROS1 gene fusion in a subset of lung cancers has raised clinical interest, because ROS1 fusion-positive cancers are reportedly sensitive to kinase inhibitors. To better understand these tumors, we examined 799 surgically resected non-small cell lung cancers by reverse transcriptase polymerase chain reaction and identified 15 tumors harboring ROS1 fusion transcripts (2.5% of adenocarcinomas). The most frequent fusion partner was CD74 followed by EZR. The affected patients were often younger nonsmoking female individuals, and they had overall survival rates similar to those of the ROS1 fusion-negative cancer patients. All the ROS1 fusion-positive tumors were adenocarcinomas except 1, which was an adenosquamous carcinoma. Histologic examination identified an at least focal presence of either solid growth with signet-ring cells or cribriform architecture with abundant extracellular mucus in 53% of the cases. These 2 patterns are reportedly also characteristic of anaplastic lymphoma kinase (ALK)-rearranged lung cancers, and our data suggest a phenotypic resemblance between the ROS1-rearranged and ALK-rearranged tumors. All tumors except 1 were immunoreactive to thyroid transcription factor-1. Fluorescence in situ hybridization using ROS1 break-apart probes revealed positive rearrangement signals in 23% to 93% of the tumor cells in ROS1 fusion-positive cancers, which were readily distinguished using a 15% cutoff value from 50 ROS1 fusion-negative tumors tested, which showed 0% to 6% rearrangement signals. However, this perfect test performance was achieved only when isolated 3′ signals were included along with classic split signals in the definition of rearrangement positivity. Fluorescence in situ hybridization signal patterns were unrelated to 5′ fusion partner genes. All ROS1 fusion-positive tumors lacked alteration of EGFR, KRAS, HER2, ALK, and RET genes.

AB - Recent discovery of ROS1 gene fusion in a subset of lung cancers has raised clinical interest, because ROS1 fusion-positive cancers are reportedly sensitive to kinase inhibitors. To better understand these tumors, we examined 799 surgically resected non-small cell lung cancers by reverse transcriptase polymerase chain reaction and identified 15 tumors harboring ROS1 fusion transcripts (2.5% of adenocarcinomas). The most frequent fusion partner was CD74 followed by EZR. The affected patients were often younger nonsmoking female individuals, and they had overall survival rates similar to those of the ROS1 fusion-negative cancer patients. All the ROS1 fusion-positive tumors were adenocarcinomas except 1, which was an adenosquamous carcinoma. Histologic examination identified an at least focal presence of either solid growth with signet-ring cells or cribriform architecture with abundant extracellular mucus in 53% of the cases. These 2 patterns are reportedly also characteristic of anaplastic lymphoma kinase (ALK)-rearranged lung cancers, and our data suggest a phenotypic resemblance between the ROS1-rearranged and ALK-rearranged tumors. All tumors except 1 were immunoreactive to thyroid transcription factor-1. Fluorescence in situ hybridization using ROS1 break-apart probes revealed positive rearrangement signals in 23% to 93% of the tumor cells in ROS1 fusion-positive cancers, which were readily distinguished using a 15% cutoff value from 50 ROS1 fusion-negative tumors tested, which showed 0% to 6% rearrangement signals. However, this perfect test performance was achieved only when isolated 3′ signals were included along with classic split signals in the definition of rearrangement positivity. Fluorescence in situ hybridization signal patterns were unrelated to 5′ fusion partner genes. All ROS1 fusion-positive tumors lacked alteration of EGFR, KRAS, HER2, ALK, and RET genes.

KW - carcinoma

KW - diagnosis

KW - lung

KW - ROS1

UR - http://www.scopus.com/inward/record.url?scp=84875224942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875224942&partnerID=8YFLogxK

U2 - 10.1097/PAS.0b013e3182758fe6

DO - 10.1097/PAS.0b013e3182758fe6

M3 - Article

C2 - 23426121

AN - SCOPUS:84875224942

VL - 37

SP - 554

EP - 562

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 4

ER -